158 related articles for article (PubMed ID: 25616967)
21. Comprehensive analysis for histone acetylation of human colon cancer cells treated with a novel HDAC inhibitor.
Zhao Y; Fang X; Wang Y; Zhang J; Jiang S; Liu Z; Ma Z; Xu L; Li E; Zhang K
Curr Pharm Des; 2014; 20(11):1866-73. PubMed ID: 23888955
[TBL] [Abstract][Full Text] [Related]
22. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.
Ying Y; Taori K; Kim H; Hong J; Luesch H
J Am Chem Soc; 2008 Jul; 130(26):8455-9. PubMed ID: 18507379
[TBL] [Abstract][Full Text] [Related]
23. Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole.
Taori K; Liu Y; Paul VJ; Luesch H
Chembiochem; 2009 Jul; 10(10):1634-9. PubMed ID: 19514039
[TBL] [Abstract][Full Text] [Related]
24. Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of N-heterocyclic carbene mediated acylations in complex molecule synthesis.
Wang B; Huang PH; Chen CS; Forsyth CJ
J Org Chem; 2011 Feb; 76(4):1140-50. PubMed ID: 21244075
[TBL] [Abstract][Full Text] [Related]
25. Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
Reddy DN; Ballante F; Chuang T; Pirolli A; Marrocco B; Marshall GR
J Med Chem; 2016 Feb; 59(4):1613-33. PubMed ID: 26681404
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold.
Bowers AA; West N; Newkirk TL; Troutman-Youngman AE; Schreiber SL; Wiest O; Bradner JE; Williams RM
Org Lett; 2009 Mar; 11(6):1301-4. PubMed ID: 19239241
[TBL] [Abstract][Full Text] [Related]
27. Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells.
Zeng X; Yin B; Hu Z; Liao C; Liu J; Li S; Li Z; Nicklaus MC; Zhou G; Jiang S
Org Lett; 2010 Mar; 12(6):1368-71. PubMed ID: 20184338
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole.
Bowers AA; Greshock TJ; West N; Estiu G; Schreiber SL; Wiest O; Williams RM; Bradner JE
J Am Chem Soc; 2009 Mar; 131(8):2900-5. PubMed ID: 19193120
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Yao Y; Tu Z; Liao C; Wang Z; Li S; Yao H; Li Z; Jiang S
J Med Chem; 2015 Oct; 58(19):7672-80. PubMed ID: 26331334
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of c7-demethyl largazole analogues.
Chen F; Gao AH; Li J; Nan FJ
ChemMedChem; 2009 Aug; 4(8):1269-72. PubMed ID: 19431162
[No Abstract] [Full Text] [Related]
31. Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
Liu Y; Tong Y; Yang X; Li F; Zheng L; Liu W; Wu J; Ou R; Zhang G; Hu M; Liu Z; Lu L
Pharmacol Res; 2016 Sep; 111():113-125. PubMed ID: 27268146
[TBL] [Abstract][Full Text] [Related]
32. A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects.
Miao JF; Peng YF; Chen S; Gao WJ; Yang QX; Zhu P; Guo J; Tao J; Luo L; Zhang Y; Ling Y
Eur J Pharmacol; 2018 Apr; 824():78-88. PubMed ID: 29428472
[TBL] [Abstract][Full Text] [Related]
33. Largazole pharmacokinetics in rats by LC-MS/MS.
Yu M; Salvador LA; Sy SK; Tang Y; Singh RS; Chen QY; Liu Y; Hong J; Derendorf H; Luesch H
Mar Drugs; 2014 Mar; 12(3):1623-40. PubMed ID: 24658499
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
Duan W; Li J; Inks ES; Chou CJ; Jia Y; Chu X; Li X; Xu W; Zhang Y
J Med Chem; 2015 May; 58(10):4325-38. PubMed ID: 25906087
[TBL] [Abstract][Full Text] [Related]
35. A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo.
Ling C; Chen G; Chen G; Zhang Z; Cao B; Han K; Yin J; Chu A; Zhao Y; Mao X
Int J Cancer; 2012 Nov; 131(10):2411-9. PubMed ID: 22362357
[TBL] [Abstract][Full Text] [Related]
36. Suppression of Musashi‑2 by the small compound largazole exerts inhibitory effects on malignant cells.
Wang M; Sun XY; Zhou YC; Zhang KJ; Lu YZ; Liu J; Huang YC; Wang GZ; Jiang S; Zhou GB
Int J Oncol; 2020 May; 56(5):1274-1283. PubMed ID: 32319553
[TBL] [Abstract][Full Text] [Related]
37. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
[TBL] [Abstract][Full Text] [Related]
38. Molecular dynamics study of HDAC8-largazole analogues co-crystals for designing potential anticancer compounds.
Dewaker V; Srivastava PN; Verma S; Prabhakar YS
J Biomol Struct Dyn; 2020 Mar; 38(4):1197-1213. PubMed ID: 30909817
[TBL] [Abstract][Full Text] [Related]
39. Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties.
Salvador LA; Park H; Al-Awadhi FH; Liu Y; Kim B; Zeller SL; Chen QY; Hong J; Luesch H
ACS Med Chem Lett; 2014 Aug; 5(8):905-10. PubMed ID: 25147612
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers.
Sanchez GJ; Richmond PA; Bunker EN; Karman SS; Azofeifa J; Garnett AT; Xu Q; Wheeler GE; Toomey CM; Zhang Q; Dowell RD; Liu X
Nucleic Acids Res; 2018 Feb; 46(4):1756-1776. PubMed ID: 29240919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
